Category: Products & Tech

Takeda_Logo

Actos Ongoing FDA Safety Review: Potential Increased Risk of Bladder Cancer

The FDA notified healthcare professionals and patients that the Agency is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone) is associated with an increased risk of bladder cancer. Findings from studies in animals and humans suggest this is a potential safety risk that needs further study. At this time, FDA has not concluded that Actos increases the risk of bladder cancer...
0 Shares
Santarus - logo

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET(R) (bromocriptine mesylate) tablets in the U.S. CYCLOSET is a prescription drug...
0 Shares
Novo Nordisk Logo

Novo Nordisk Creates “App” to Help Doctors Dose Insulin

Novo Nordisk announced today the availability of NovoDoseTM – the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk’s modern insulin analog portfolio...
0 Shares
gsk-logo

Actos as Dangerous as Avandia, New Study Shows

The continuing controversy surrounding the cardiovascular risk of GlaxoSmithKline's diabetes drug Avandia has led to sharp declines in its use and a surge in sales of the competing drug, Actos. Although the drugs are similar and both had FDA warnings in 2007, Takeda's Actos has been...
0 Shares
JDRF New Logo

Wireless CGM Sensor – A Milestone on the Way to an Artificial Pancreas

Researchers from the University of California San Diego and GlySens Inc. have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires, according to a Reuters report . The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, and the researchers hope to start a human study within a few months...
0 Shares